Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia

Molecular Psychiatry

Volumn 14, Issue 11, 2009, Pages 1017-1023

  Scarr, E ^a,b   Cowie, T F ^a,c   Kanellakis, S ^a,c   Sundram, S ^a,b,d   Pantelis, C ^a   Dean, B ^a,b,c,e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c National Neuroscience Facility Australia   (Australia)

^d NORTHERN HOSPITAL   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

Acetylcholine; CHRM1; Cortex; Human; Post mortem; Psychiatric disorders

Indexed keywords

[3 H]PIRENZEPINE; MUSCARINIC M1 RECEPTOR; PIRENZEPINE; UNCLASSIFIED DRUG;

ARTICLE; CADAVER; CONTROLLED STUDY; DISEASE DURATION; GENE SEQUENCE; GENOTYPE; HUMAN; KERNEL METHOD; MUSCARINIC RECEPTOR DEFICIT SCHIZOPHRENIA; NEUROIMAGING; NUCLEOTIDE SEQUENCE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA; SUICIDE;

ADULT; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; DOWN-REGULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PIRENZEPINE; POSTMORTEM CHANGES; PREFRONTAL CORTEX; PROTEIN BINDING; RECEPTOR, MUSCARINIC M1; SCHIZOPHRENIA; TRITIUM;

EID: 70350446516     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2008.28     Document Type: Article

References (43)

1. Jablensky A. Subtyping schizophrenia: implications for genetic research. Mol Psychiatry 2006; 11: 815-836.
2. Drut R, Rua EC. Histopathologic diagnosis of celiac disease in children without clinical evidence of malabsorption. Int J Surg Pathol 2007; 15: 354-357.
3. Pope FM, Nicholls AC, McPheat J, Talmud P, Owen R. Collagen genes and proteins in osteogenesis imperfecta. J Med Genet 1985; 22: 466-478.
4. Hallmayer JF, Kalaydjieva L, Badcock J, Dragovic M, Howell S, Michie PT et al. Genetic evidence for a distinct subtype of schizophrenia characterized by pervasive cognitive deficit. Am J Hum Genet 2005; 77: 468-476.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn (text revision). American Psychiatric Association: Washington, DC, 2000.
6. Mirza NR, Peters D, Sparks RG. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev 2003; 9: 159-186.
7. Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl) 2004; 177: 207-216.
8. Raedler TJ, Knable MB, Jones DW, Urbina RA, Gorey JG, Lee KS et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 2003; 160: 118-127.
9. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 2000; 48: 381-388.
10. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 2001; 158: 918-925.
11. Zavitsanou K, Katsifis A, Mattner F, Xu-Feng H. Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 2004; 29: 619-625.
12. Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B. Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry 2006; 12: 232-246.
13. Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E. Decreased muscarinic(1) receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 2002; 7: 1083-1091.
14. Scarr E, Keriakous D, Crossland N, Dean B. No change in cortical muscarinic M2, M3 receptors or [(35)S]GTPgammaS binding in schizophrenia. Life Sci 2006; 78: 1231-1237.
15. Mancama D, Arranz MJ, Landau S, Kerwin R. Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003; 119: 2-6.
16. Liao DL, Hong CJ, Chen HM, Chen YE, Lee SM, Chang CY et al. Association of muscarinic m1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients. Neuropsychobiology 2003; 48: 72-76.
17. Kingsbury AE, Foster OJ, Nisbet AP, Cairns N, Bray L, Eve DJ et al. Tissue pH as an indicator of mRNA preservation in human postmortem brain. Brain Res Mol Brain Res 1995; 28: 311-318.
18. Hill C, Keks N, Roberts S, Opeskin K, Dean B, Copolov D. Diagnostic Instrument for Brain Studies. Mental Health Research Institute: Melbourne, 1999.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn American Psychiatric Association: Washington, DC, 1994.
20. Remington GJ. Antipsychotics (Neuroleptics). In Bezchlibnyk-Butler KZ and Jeffries JJ (eds). Clincal Handbook of Psychotropic Drugs. Hogrefe & Huber: Seattle, Toronto, Göttingen, Bern, 1999, pp 55-84.
21. Strauss WM. Preparation of Genomic DNA from mammalian tissue. In: Crawley JN, Gerfen CR, Rogawski MA, Sibley DR, Skolnick P, and Way S (eds). Current Protocols in Neuroscience. John Wiley & Sons, Inc.: Hoboken, 1999, pp A.1H.1-A.1H.3.
22. Dean B, Crook JM, Opeskin K, Hill C, Keks N, Copolov DL. The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry 1996; 1: 54-58.
23. Rodbard D. Mathematics and statistics of ligand assays. In: Langan J and Clapp JJ (eds). Ligand Assay: Analysis of International Developments on Isotopic and Nonisotopic Immunoassay. Masson: New York, 1981, pp 55-101.
24. Dean B, Pavey G, Opeskin K. [3H]raclopride binding to brain tissue from subjects with schizophrenia: methodological aspects. Neu-ropharmacology 1997; 36: 779-786.
25. Dean B, Soulby A, Evin G, Scarr E. Changed cholinergic markers in Brodmann's area 6 from subjects with schizophrenia. Neu-roscience Meeting Planner San Diego, CA: Society for Neu-roscience, 2007 CD-ROM. 118.8; abstract.
26. Bennett Jr JP, Enna SJ, Bylund DB, Gillin JC, Wyatt RJ, Snyder SH. Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 1979; 36: 927-934.
27. Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I. Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci 1999; 64: 2351-2358.
28. Scarr E, Sundram S, Keriakous D, Dean B. Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. Biol Psychiatry 2007; 61: 1161-1170.
29. Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem 1995; 64: 1888-1891.
30. Lucas JL, DeYoung JA, Sadee W. Single nucleotide polymorphisms of the human M1 muscarinic acetylcholine receptor gene. AAPS PharmSci 2001; 3: E31.
31. Hughes JR, Frances RJ. How to help psychiatric patients stop smoking. Psychiatr Serv 1995; 46: 435-436.
32. Falk L, Nordberg A, Seiger A, Kjaeldgaard A, Hellstrom-Lindahl E. Smoking during early pregnancy affects the expression pattern of both nicotinic and muscarinic acetylcholine receptors in human first trimester brainstem and cerebellum. Neuroscience 2005; 132: 389-397.
33. Zavitsanou K, Nguyen VH, Han M, Huang XF. Effects of typical and atypical antipsychotic drugs on rat brain muscarinic receptors. Neurochem Res 2007; 32: 525-532.
34. Han M, Newell K, Zavitsanou K, Deng C, Huang XF. Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain. J Neurosci Res 2007\; 86: 457-464, e-pub ahead of print, doi: 10.1002/jnr.21491.
35. Lee W, Wolfe BB. Regulation of muscarinic receptor subtypes and their responsiveness in rat brain following chronic atropine administration. Mol Pharmacol 1989; 36: 749-757.
36. Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 2003; 6: 51-58.
37. MacDonald III AW, Cohen JD, Stenger VA, Carter CS. Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control. Science 2000; 288: 1835-1838.
38. Dean B, Scarr E. Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits. Curr Drug Targets CNS Neurol Disord 2004; 3: 217-225.
39. Gray JA, Roth BL. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 2007; 33: 1100-1119.
40. Bymaster FP, McKinzie K, Rasmussen K, Tzavara ET, Nomikos GG, Shekhar A et al. Antipsychotic activity of muscarinic agonists in animals and humans. Int J Neuropsychopharmacol 2004; 7(suppl 1): S16-S17. abstract.
41. Bymaster FP, Felder C, Ahmed S, McKinzie D. Muscarinic receptors as a target for drugs treating schizophrenia. Curr Drug Targets CNS and Neurol Disord 2002; 1: 163-181.
42. Tzavara ET, Bymaster FP, Davis RJ, Wade MR, Perry KW, Wess J et al. M4 muscarinic receptors regulate the dynamics of choli-nergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J 2004; 18: 1410-1412.
43. Zubieta JK, Koeppe RA, Frey KA, Kilbourn MR, Mangner TJ, Foster NL et al. Assessment of muscarinic receptor concentrations in aging and Alzheimer disease with [11C]NMPB and PET. Synapse 2001; 39: 275-287.